The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective

Fatima, Saeeda; Jameel, Ayesha; Ayesha, Fnu; Menzies, Dhananjai J.

doi:10.1002/clc.22781

Cited by 3 publications

(2 citation statements)

References 39 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the quality measures assessed in this study target chronic disease management, they are also directly pertinent to the prevention of cardiovascular events. While diabetes may have been more commonly managed within primary care settings in the past, findings from recent studies of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors and glucagon‐like peptide‐1 (GLP‐1) receptor agonists have shown that these medications reduce the risk of cardiovascular events in high‐risk patients with diabetes . Based on these data, use of these medications is likely to increase among cardiologists, and the coordination between cardiologists and PCPs when initiating and monitoring these medications will be critical.…”

Section: Discussionmentioning

confidence: 99%

“…While diabetes may have been more commonly managed within primary care settings in the past, findings from recent studies of sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have shown that these medications reduce the risk of cardiovascular events in high-risk patients with diabetes. 17,18 Based on these data, use of these medications is likely to increase among cardiologists, and the coordination between cardiologists and PCPs when initiating and monitoring these medications will be critical. Additionally, influenza vaccination reduces the risk of secondary myocardial infarction in patients with CAD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of chronic disease management among patients with diabetes and coronary artery disease receiving care in a cardiology clinic

Pearson

Shakowski

Griend

et al. 2018

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Background Patients with coronary artery disease (CAD) often have multiple comorbidities (eg, diabetes, hypertension, and hyperlipidemia). It is unclear if these comorbidities are adequately managed among patients established in a cardiology clinic. Methods This retrospective, observational study used electronic medical record data from 1 January 2014 to 31 October 2017 to examine the achievement of five chronic disease quality measures (glycated hemoglobin, A1C ≤ 9.0%, blood pressure, BP < 140/90 mm Hg, antiplatelet agent, moderate/high‐intensity statin, and annual influenza vaccine). Additional measures of optimal care were also assessed (A1C ≤ 8.0%, A1C ≤ 7.0%, blood pressure < 130/80 mm Hg, high‐intensity statin, pneumococcal polysaccharide vaccination (PPSV23)). Patients were identified from the University of Colorado Health Cardiac and Vascular Center (CVC) with CAD, diabetes, and at least two CVC visits within a 24‐month period (n = 295). Results The primary outcome measures with highest achievement were for antiplatelet and moderate/high‐intensity statin prescribing (91% and 89%, respectively). The measure with lowest achievement was receipt of influenza vaccination (69%). Women were less likely than men to achieve at least four of the five measures (adjusted odds ratio [OR], 0.44; 95% confidence interval [CI], 0.24‐0.80). Patients with two or more primary care provider (PCP) visits within the past year were more likely to achieve at least four measures compared with patients with less than two PCP visits (adjusted OR, 2.22; 95% CI, 1.14‐4.31). When applying optimal measures, 41% of patients achieved an A1C ≤7%, 52% achieved a blood pressure of <130/80 mm Hg, and 66% were prescribed high‐intensity statins. Conclusions Achievement for chronic care quality measures was high but performance could be improved, especially among women and patients with infrequent PCP visits. Increased collaboration and communication between primary care and cardiology may improve care for these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Assessment of chronic disease management among patients with diabetes and coronary artery disease receiving care in a cardiology clinic

Pearson

Shakowski

Griend

et al. 2018

J Am Coll Clin Pharm

View full text Add to dashboard Cite

show abstract

Aging Fits the Disease Criteria of the International Classification of Diseases

Khaltourina

Matveyev

Alekseev

et al. 2020

Mechanisms of Ageing and Development

View full text Add to dashboard Cite

Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents

Abdelfattah

Sayed

Al-Refaei

et al. 2023

Frontiers in Clinical Drug Research-Diabetes and Obesity: Volume 7

View full text Add to dashboard Cite

Diabetes and hyperlipidemia are global epidemics that significantly increase the morbidity and mortality of the affected population. Several medications have been utilized to mitigate the risk of diabetes and hyperlipidemia. Insulin, alpha-glucosidase inhibitors, thiazolidinediones have been used for decades as antidiabetic medications. Statins are a cornerstone in hyperlipidemia management. Omega‐3 fatty acid supplementation has been used to treat hypertriglyceridemia with debatable effects on cardiovascular outcomes. In the past decade, multiple new discoveries have revolutionized the management of these disorders. Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a class of oral anti-diabetic drugs with a unique mechanism of action. SGLT2 was proven to reduce cardiovascular events, including hospitalization for heart failure, with this benefit extending to patients without diabetes. PCSK9 inhibitors are a new class of antihyperlipidemic that significantly lowers plasma LDL-C on top of the conventional treatment. In this book chapter, we review the history of diabetes and hyperlipidemia medications and discuss the new classes of lipid-lowering and anti-diabetic medications and their associated cardioprotective benefits.

show abstract

The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective

Cited by 3 publications

References 39 publications

Assessment of chronic disease management among patients with diabetes and coronary artery disease receiving care in a cardiology clinic

Assessment of chronic disease management among patients with diabetes and coronary artery disease receiving care in a cardiology clinic

Aging Fits the Disease Criteria of the International Classification of Diseases

Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents

Contact Info

Product

Resources

About